Donald L Matthews

US Patent:

6417212, Jul 9, 2002

Filed:

Aug 23, 2000

Appl. No.:

09/644457

Inventors:

Dawn A. Brooks - Indianapolis IN
Christopher J. Rito - Martinsville IN
Anthony J. Shuker - Atlanta GA
Samuel J. Dominianni - Indianapolis IN
Alan M. Warshawsky - Carmel IN
Lynn S. Gossett - Indianapolis IN
Donald P. Matthews - Indianapolis IN
David A. Hay - Indianapolis IN
Robert J. Ardecky - Encinitas CA
Pierre-Yves Michellys - San Diego CA
John S. Tyhonas - San Diego CA

Assignee:

Eli Lilly Company - Indianapolis IN
Ligand Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D26336

US Classification:

514374, 548235

Abstract:

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO ; R is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R is H, a C1-C4 alkyl, or an aminoalkyl.

US Patent:

6610696, Aug 26, 2003

Filed:

Apr 11, 2002

Appl. No.:

10/121373

Inventors:

Dawn A. Brooks - Indianapolis IN
Christopher J. Rito - Martinsville IN
Anthony J. Shuker - Atlanta GA
Samuel J. Dominianni - Indianapolis IN
Alan M. Warshawsky - Carmel IN
Lynn S. Gossett - Indianapolis IN
Donald P. Matthews - Indianapolis IN
David A. Hay - Indianapolis IN
Robert J. Ardecky - Encinitas CA
Pierre-Yves Michellys - San Diego CA
John S. Tyhonas - San Diego CA

Assignee:

Eli Lilly and Company - Indianapolis IN
Ligand Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 3142

US Classification:

514256, 548236, 544333, 546198, 514374, 514338

Abstract:

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO ; R is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R is H, a C1-C4 alkyl, or an aminoalkyl.

US Patent:

6825222, Nov 30, 2004

Filed:

May 7, 2003

Appl. No.:

10/434425

Inventors:

Dawn A. Brooks - Indianapolis IN
Christopher J. Rito - Martinsville IN
Anthony J. Shuker - Atlanta GA
Samuel J. Dominianni - Indianapolis IN
Alan M. Warshawsky - Carmel IN
Lynn S. Gossett - Indianapolis IN
Donald P. Matthews - Indianapolis IN
David A. Hay - Indianapolis IN
Robert J. Ardecky - Encinitas CA
Pierre-Yves Michellys - San Diego CA
John S. Tyhonas - San Diego CA

Assignee:

Eli Lilly and Company - Indianapolis IN
Ligand Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31425

US Classification:

514365, 548204

Abstract:

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO ; R is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R is H, a C1-C4 alkyl, or an aminoalkyl.

US Patent:

7282501, Oct 16, 2007

Filed:

May 24, 2002

Appl. No.:

10/477405

Inventors:

Lynn Stacy Gossett - Indianapolis IN, US
Jonathan Edward Green - Greencastle IN, US
James Robert Henry - Indianapolis IN, US
Winton Dennis Jones - Carmel IN, US
Donald Paul Matthews - Indianapolis IN, US
Quanrong Shen - Fishers IN, US
Daryl Lynn Smith - Fishers IN, US
Jennifer Ann Vance - San Jose CA, US
Alan M. Warshawsky - Carmel IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/535
A61K 31/42
A61K 31/445
A61K 31/4965
C07D 263/34
C07D 275/04
C07D 413/10

US Classification:

5142368, 514374, 514326, 514256, 51425505, 514340, 548236, 548209, 544137, 544333, 544405, 5462714

Abstract:

The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

US Patent:

7411072, Aug 12, 2008

Filed:

Jun 13, 2003

Appl. No.:

10/517010

Inventors:

Michael Joseph Coghlan - Fishers IN, US
Jonathan Edward Green - Avon IN, US
Timothy Alan Grese - Indianapolis IN, US
Prabhakar Kondaji Jadhav - Zionsville IN, US
Donald Paul Matthews - Indianapolis IN, US
Mitchell Irvin Steinberg - Indianapolis IN, US
Kevin Robert Fales - Avon IN, US
Michael Gregory Bell - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A01N 43/52
C07D 235/04

US Classification:

5483051, 514395

Abstract:

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula:.

US Patent:

7482344, Jan 27, 2009

Filed:

Dec 15, 2004

Appl. No.:

10/576901

Inventors:

Michael Joseph Coghlan - Fishers IN, US
Prabhakar Kondaji Jadhav - Zionsville IN, US
James Joseph Droste - Indianapolis IN, US
Jonathan Edward Green - Avon IN, US
Donald Paul Matthews - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/423
A61K 31/431
A61K 31/496
A61K 31/4433
C07D 265/30
C07D 401/14
C07D 417/10

US Classification:

5142345, 51425406, 514338, 514367, 514375, 514437, 544107, 544366, 5462737, 548159, 549 16

Abstract:

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

US Patent:

7655641, Feb 2, 2010

Filed:

Feb 10, 2004

Appl. No.:

10/542579

Inventors:

Scott Eugene Conner - Indianapolis IN, US
Lynn Stacy Gossett - Indianapolis IN, US
Jonathan Edward Green - Avon IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Donald Paul Matthews - Indianapolis IN, US
Daniel Ray Mayhugh - Carmel IN, US
Daryl Lynn Smith - Fishers IN, US
Jennifer Ann Vance - San Jose CA, US
Xiaodong Wang - Carmel IN, US
Alan M Warshawsky - Carmel IN, US
Yanping Xu - Fishers IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/66
A61K 31/38
C07D 409/12
C07D 209/04

US Classification:

514141, 514443, 548467, 549 51, 549 52, 549 54, 549 55

Abstract:

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

US Patent:

7803814, Sep 28, 2010

Filed:

Dec 8, 2004

Appl. No.:

10/576761

Inventors:

Konstantinos Gavardinas - Monrovia IN, US
Jonathan Edward Green - Avon IN, US
Prabhakar Kondaji Jadhav - Zionsville IN, US
Donald Paul Matthews - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/445
C07D 401/14

US Classification:

514320, 546196

Abstract:

The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).